In this Project, we will investigate molecular mechanisms by which PPARs counter-regulate innate immune responses and influence the ability of macrophages to contribute to atherosclerotic vascular disease. There is now extensive evidence that PPARa, PPARy and PPARd ligands inhibit inflammatory processes in macrophages and other cells within the artery wall that are linked to the progression of atherosclerosis and its clinical complications, but the mechanisms that are responsible for these effects remain poorly understood. We recently identified an NCoR/SUMOylation-dependent pathway by which PPARy ligands inhibit specific subsets of toll-like receptor (TLR) 4-responsive genes. This mechanism involves ligand-dependent sumoylation of PPARy, which targets it to NCoR corepressor complexes on the promoters of inflammatory response genes. This in turn prevents the signal-dependent removal of NCoR complexes that is normally a prerequisite for transcriptional activation.
Three Specific Aims are proposed to explore the significance of these findings with respect to the control of inflammatory programs of gene expression that underlie innate immune responses and the development of atherosclerosis.:
Specific Aim 1 will utilize a combination of molecular, cellular and genomics approaches to test the hypothesis that NCoR, and the highly related corepressor SMRT, are differentially required to maintain inflammatory response genes silent under quiescent conditions. In collaboration with Project 3, we will test the hypothesis that NCoR and SMRT are actively removed from these promoters upon stimulation of macrophages and B1 cells by modified LDL and specific TLR2 and TLR4 agonists. We will test the hypothesis that the NCoR/SMRT repression checkpoint is inappropriately relieved in macrophage foam cells in vivo, resulting in a partially activated phenotype.
Specific Aim 2 will test the hypothesis that the NCoR/SMRT/SUMOylation dependent pathway is a quantitatively important mechanism mediating anti-inflammatory actions of PPARy and PPARd agonists in macrophages. In collaboration with Project 2, we will define the genome-wide profiles of PPARy and PPARS repression of genes activated by the TLR2 agonist Pam3 in NCoR[-/-] and SMRT[-/-] macrophages. We will determine the ability of PPARy and PPARd-specific agonists to exert anti-inflammatory effects in macrophages lacking the SUMO E3 ligase PIAS1.
Specific Aim 3 will test the hypothesis that the NCoR/SMRT/SUMOylation-dependent pathway plays a quantitatively important role in mediating antiatherogenic effects of PPARy agonists in vivo. In collaboration with Project 4, we will use a combination of selective PPARy modulators and PPARy mutants to define the relative importance of ligand-dependent activation and ligand-dependent repression in inhibiting the development of atherosclerosis in LDL receptordeficient (LDLR[-/-]) mice. The results of these studies are likely to contribute to an improved understanding of the inflammatory component of atherosclerosis and the anti-atherogenic actions of PPARy agonists.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL088093-04
Application #
8251180
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
4
Fiscal Year
2011
Total Cost
$393,534
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Ahmadian, Maryam; Liu, Sihao; Reilly, Shannon M et al. (2018) ERR? Preserves Brown Fat Innate Thermogenic Activity. Cell Rep 22:2849-2859
Kobiyama, Kouji; Ley, Klaus (2018) Atherosclerosis. Circ Res 123:1118-1120
Woller, Sarah A; Choi, Soo-Ho; An, Eun Jung et al. (2018) Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States. Cell Rep 23:2667-2677
Jeong, Se-Jin; Kim, Sinai; Park, Jong-Gil et al. (2018) Prdx1 (peroxiredoxin 1) deficiency reduces cholesterol efflux via impaired macrophage lipophagic flux. Autophagy 14:120-133
Choi, Soo-Ho; Wallace, Aaron M; Schneider, Dina A et al. (2018) AIBP augments cholesterol efflux from alveolar macrophages to surfactant and reduces acute lung inflammation. JCI Insight 3:
Muse, Evan D; Yu, Shan; Edillor, Chantle R et al. (2018) Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages. Proc Natl Acad Sci U S A 115:E4680-E4689
Wei, Zong; Yoshihara, Eiji; He, Nanhai et al. (2018) Vitamin D Switches BAF Complexes to Protect ? Cells. Cell 173:1135-1149.e15
Tsimikas, Sotirios; Fazio, Sergio; Ferdinand, Keith C et al. (2018) NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol 71:177-192
Winkels, Holger; Ley, Klaus (2018) Natural Killer Cells at Ease: Atherosclerosis Is Not Affected by Genetic Depletion or Hyperactivation of Natural Killer Cells. Circ Res 122:6-7
Liu, Chao; Han, Tianxu; Stachura, David L et al. (2018) Lipoprotein lipase regulates hematopoietic stem progenitor cell maintenance through DHA supply. Nat Commun 9:1310

Showing the most recent 10 out of 172 publications